Clinical-pathogenetic and prognostic value of the nitrotyrosine level in the blood serum of patients with coronavirus disease (COVID-19) with pneumonia

Authors

DOI:

https://doi.org/10.14739/2310-1237.2024.2.299314

Keywords:

coronavirus disease, COVID-19, viral infection, pneumonia, oxidative stress, nitrotyrosine, diagnosis, prognosis

Abstract

The aim of the research is to determine the clinical-pathogenetic and prognostic value of nitrotyrosine levels in the blood serum of patients with COVID-19 with pneumonia in the development of oxygen dependence and the risk of fatal outcome.

Materials and methods. 123 patients with COVID-19 with pneumonia were examined, who were examined and treated according to the Order of the Ministry of Health of Ukraine dated March 28, 2020 No. 722. Patients were divided into groups: I group – 32 patients with a moderate course without oxygen dependence; II group – 91 patients with a severe course with the presence of oxygen dependence. Patients in the II group were additionally divided into subgroups: II-A subgroup – 45 patients who recovered; II-B subgroup – 46 patients who died. The content of nitrotyrosine (Hycult Biotech, the Netherlands) was determined in the blood serum by the immunoenzymatic method. Statistical data processing was carried out in the program Statistica for Windows 13 (StatSoft Inc., No. JPZ804I382130ARCN10-J).

Results. The content of nitrotyrosine in the blood serum of patients with COVID-19 with pneumonia in a severe course with the development of oxygen dependence is higher (p < 0.001) than in patients with a moderate course of the disease without signs of oxygen dependence. The level of its increase has an inverse correlation with the oxygen saturation index (r = -0.53, р < 0.05). When hospitalized for 9.0 [7.0; 12.0] day of the disease, under the condition of nitrotyrosine level >481.97 nmol/ml (AUC = 0.909, p < 0.001), the probability of developing oxygen dependence is significant. And under the conditions of nitrotyrosine level >521.96 nmol/ml during this observation period, the probability of a fatal outcome of the disease is significant (AUC = 0.842, p < 0.001). The established correlations confirm the clinical-pathogenetic role of nitrotyrosative stress in the development of the “cytokine storm” and multiorgan failure. The content of nitrotyrosine correlates with the level of C-reactive protein (r = +0.25, p < 0.05), the ratio of absolute neutrophil count to absolute lymphocyte count (r = +0.26, p < 0.05), alanine aminotransferase activity (r = +0.26, p < 0.05) and glomerular filtration rate (r = -0.27, p < 0.05). The diagnostic value of determining the level of nitrotyrosine in predicting the course of COVID-19 with pneumonia against the background of treatment after 7 days lies in the possibility of predicting the probability of a fatal outcome of the disease. Namely, the preservation of the level of nitrotyrosine >507.98 nmol/ml (AUC = 0.681, p < 0.001) during the specified period of observation indicates a high probability of a fatal outcome of the disease.

Conclusions. In patients with COVID-19 with pneumonia, the level of nitrotyrosine elevation in the blood serum depends on the appearance of oxygen dependence and the outcome of the disease. The highest level of nitrotyrosine is in patients with COVID-19 with pneumonia with a severe course, and the degree of increase of this indicator has diagnostic value in predicting the probability of an unfavorable disease course.

Author Biographies

O. V. Riabokon, Zaporizhzhia State Medical and Pharmaceutical University, Ukraine

MD, PhD, DSc, Professor, Head of the Department of Infectious Diseases

I. O. Kuliesh, Zaporizhzhia State Medical and Pharmaceutical University, Ukraine

MD, Graduate Student of the Department of Infectious Diseases

I. F. Bielenichev, Zaporizhzhia State Medical and Pharmaceutical University, Ukraine

PhD, DSc, Professor, Head of the Department of Pharmacology and Medical Formulation with Course of Normal Physiology

Yu. Yu. Riabokon, Zaporizhzhia State Medical and Pharmaceutical University, Ukraine

MD, PhD, DSc, Professor of the Department of Children Infectious Diseases

References

Niedźwiedzka-Rystwej P, Majchrzak A, Kurkowska S, Małkowska P, Sierawska O, Hrynkiewicz R, et al. Immune Signature of COVID-19: In-Depth Reasons and Consequences of the Cytokine Storm. Int J Mol Sci. 2022;23(9):4545. doi: https://doi.org/https://doi.org/10.3390/ijms23094545

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-20. doi: https://doi.org/https://doi.org/10.1056/NEJMoa2002032

Niedźwiedzka-Rystwej P, Grywalska E, Hrynkiewicz R, Bębnowska D, Wołącewicz M, Majchrzak A, et al. Interplay between Neutrophils, NETs and T-Cells in SARS-CoV-2 Infection-A Missing Piece of the Puzzle in the COVID-19 Pathogenesis? Cells. 2021;10(7):1817. doi: https://doi.org/https://doi.org/10.3390/cells10071817

Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, et al. On the Alert for Cytokine Storm: Immunopathology in COVID-19. Arthritis Rheumatol. 2020;72(7):1059-63. doi: https://doi.org/https://doi.org/10.1002/art.41285

Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8(12):1233-44. doi: https://doi.org/https://doi.org/10.1016/S2213-2600(20)30404-5

Chen LY, Quach TT. COVID-19 cytokine storm syndrome: a threshold concept. Lancet Microbe. 2021;2(2):e49-e50. doi: https://doi.org/https://doi.org/10.1016/S2666-5247(20)30223-8

Kell DB, Pretorius E. The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications. Biochem J. 2022;479(16):1653-708. doi: https://doi.org/https://doi.org/10.1042/BCJ20220154

Brouqui P, Amrane S, Million M, Cortaredona S, Parola P, Lagier JC, et al. Asymptomatic hypoxia in COVID-19 is associated with poor outcome. Int J Infect Dis. 2021;102:233-8. doi: https://doi.org/https://doi.org/10.1016/j.ijid.2020.10.067

Rahman A, Tabassum T, Araf Y, Al Nahid A, Ullah MA, Hosen MJ. Silent hypoxia in COVID-19: pathomechanism and possible management strategy. Mol Biol Rep. 2021;48(4):3863-9. doi: https://doi.org/https://doi.org/10.1007/s11033-021-06358-1

Soto ME, Guarner-Lans V, Díaz-Díaz E, Manzano-Pech L, Palacios-Chavarría A, Valdez-Vázquez RR, et al. Hyperglycemia and Loss of Redox Homeostasis in COVID-19 Patients. Cells. 2022;11(6):932. doi: https://doi.org/https://doi.org/10.3390/cells11060932

Soria-Castro E, Soto ME, Guarner-Lans V, Rojas G, Perezpeña-Diazconti M, Críales-Vera SA, et al. The kidnapping of mitochondrial function associated with the SARS-CoV-2 infection. Histol Histopathol. 2021;36(9):947-65. doi: https://doi.org/https://doi.org/10.14670/HH-18-354

Narne P, Pandey V, Phanithi PB. Role of Nitric Oxide and Hydrogen Sulfide in Ischemic Stroke and the Emergent Epigenetic Underpinnings. Mol Neurobiol. 2019;56(3):1749-69. doi: https://doi.org/https://doi.org/10.1007/s12035-018-1141-6

Grau M, Ibershoff L, Zacher J, Bros J, Tomschi F, Diebold KF, et al. Even patients with mild COVID-19 symptoms after SARS-CoV-2 infection show prolonged altered red blood cell morphology and rheological parameters. J Cell Mol Med. 2022;26(10):3022-30. doi: https://doi.org/https://doi.org/10.1111/jcmm.17320

Romero N, Denicola A, Radi R. Red blood cells in the metabolism of nitric oxide-derived peroxynitrite. IUBMB Life. 2006;58(10):572-80. doi: https://doi.org/https://doi.org/10.1080/15216540600936549

Dominic P, Ahmad J, Bhandari R, Pardue S, Solorzano J, Jaisingh K, et al. Decreased availability of nitric oxide and hydrogen sulfide is a hallmark of COVID-19. Redox Biol. 2021;43:101982. doi: https://doi.org/https://doi.org/10.1016/j.redox.2021.101982

D'Ignazio L, Bandarra D, Rocha S. NF-κB and HIF crosstalk in immune responses. FEBS J. 2016;283(3):413-24. doi: https://doi.org/https://doi.org/10.1111/febs.13578

D'Ignazio L, Batie M, Rocha S. Hypoxia and Inflammation in Cancer, Focus on HIF and NF-κB. Biomedicines. 2017;5(2):21. doi: https://doi.org/https://doi.org/10.3390/biomedicines5020021

Kerins MJ, Ooi A. The Roles of NRF2 in Modulating Cellular Iron Homeostasis. Antioxid Redox Signal. 2018;29(17):1756-73. doi: https://doi.org/https://doi.org/10.1089/ars.2017.7176

Schmidlin CJ, Dodson MB, Madhavan L, Zhang DD. Redox regulation by NRF2 in aging and disease. Free Radic Biol Med. 2019;134:702-7. doi: https://doi.org/https://doi.org/10.1016/j.freeradbiomed.2019.01.016

Bizjak DA, John L, Matits L, Uhl A, Schulz SV, Schellenberg J, et al. SARS-CoV-2 Altered Hemorheological and Hematological Parameters during One-Month Observation Period in Critically Ill COVID-19 Patients. Int J Mol Sci. 2022;23(23):15332. doi: https://doi.org/https://doi.org/10.3390/ijms232315332

Kouhpayeh S, Shariati L, Boshtam M, Rahimmanesh I, Mirian M, Esmaeili Y, et al. The Molecular Basis of COVID-19 Pathogenesis, Conventional and Nanomedicine Therapy. Int J Mol Sci. 2021;22(11):5438. doi: https://doi.org/https://doi.org/10.3390/ijms22115438

Prakash A, Kaur S, Kaur C, Prabha PK, Bhatacharya A, Sarma P, et al. Efficacy and safety of inhaled nitric oxide in the treatment of severe/critical COVID-19 patients: A systematic review. Indian J Pharmacol. 2021;53(3):236-43. doi: https://doi.org/https://doi.org/10.4103/ijp.ijp_382_21

Sim JY. Nitric oxide and pulmonary hypertension. Korean Journal of Anesthesiology. 2010;58(1):4. doi: https://doi.org/https://doi.org/10.4097/kjae.2010.58.1.4

Cuschieri S, Grech S. COVID-19 and diabetes: The why, the what and the how. J Diabetes Complications. 2020;34(9):107637. doi: https://doi.org/https://doi.org/10.1016/j.jdiacomp.2020.107637

Mahrooz A, Muscogiuri G, Buzzetti R, Maddaloni E. The complex combination of COVID-19 and diabetes: pleiotropic changes in glucose metabolism. Endocrine. 2021;72(2):317-25. doi: https://doi.org/https://doi.org/10.1007/s12020-021-02729-7

Barberis E, Timo S, Amede E, Vanella VV, Puricelli C, Cappellano G, et al. Large-Scale Plasma Analysis Revealed New Mechanisms and Molecules Associated with the Host Response to SARS-CoV-2. Int J Mol Sci. 2020;21(22):8623. doi: https://doi.org/https://doi.org/10.3390/ijms21228623

Ceriello A, De Nigris V, Prattichizzo F. Why is hyperglycaemia worsening COVID-19 and its prognosis? Diabetes Obes Metab. 2020;22(10):1951-2. doi: https://doi.org/https://doi.org/10.1111/dom.14098

Paul AK, Hossain MK, Mahboob T, Nissapatorn V, Wilairatana P, Jahan R, et al. Does Oxidative Stress Management Help Alleviation of COVID-19 Symptoms in Patients Experiencing Diabetes? Nutrients. 2022;14(2):321. doi: https://doi.org/https://doi.org/10.3390/nu14020321

Delgado-Roche L, Mesta F. Oxidative Stress as Key Player in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection. Arch Med Res. 2020;51(5):384-7. doi: https://doi.org/https://doi.org/10.1016/j.arcmed.2020.04.019

Chavarría AP, Vázquez RR, Cherit JG, Bello HH, Suastegui HC, Moreno-Castañeda L, et al. Antioxidants and pentoxifylline as coadjuvant measures to standard therapy to improve prognosis of patients with pneumonia by COVID-19. Comput Struct Biotechnol J. 2021;19:1379-90. doi: https://doi.org/https://doi.org/10.1016/j.csbj.2021.02.009

Downloads

Additional Files

Published

2024-08-30

How to Cite

1.
Riabokon OV, Kuliesh IO, Bielenichev IF, Riabokon YY. Clinical-pathogenetic and prognostic value of the nitrotyrosine level in the blood serum of patients with coronavirus disease (COVID-19) with pneumonia. Pathologia [Internet]. 2024Aug.30 [cited 2024Nov.2];21(2):141-7. Available from: http://pat.zsmu.edu.ua/article/view/299314

Issue

Section

Original research